Amunix raises $73M to take T-cell engager into humans

Amunix Pharmaceuticals has raised $73 million in series A funding. The Omega Funds-led round sets Amunix up to move its lead T-cell engager into the clinic after years of licensing its half-life extension technology to leading drug developers for their own candidates.